CoChat

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells

Open access
Gonçalves-Ribeiro, Samuel, Díaz-Maroto, Natalia Guillen, Berdiel-Acer, Mireia, Soriano, Antonio, Guardiola, Jordi, Martínez-Villacampa, Mercedes, Salazar, Ramon, Capellà, Gabriel, Villanueva, Alberto, Martínez-Balibrea, Eva, Molleví, David G. · 2016 · Oncotarget
Cited by 59

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

// Samuel Gonçalves-Ribeiro 1 , Natalia Guillen Díaz-Maroto 1 , Mireia Berdiel-Acer 1 , Antonio Soriano 2 , Jordi Guardiola 2 , Mercedes Martínez-Villacampa 3 , Ramon Salazar 3 , Gabriel Capellà 4 , Alberto Villanueva 1 , Eva Martínez-Balibrea 5 , David G. Molleví 1 1 Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Catalonia, Spain 2 Gastroenterology Department, Endoscopy Unit, Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Catalonia, Spain 3 Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Catalonia, Spain 4 Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Catalonia, Spain 5 Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IGTP, Badalona, Catalonia, Spain Correspondence to: David G. Molleví, email: dgmollevi@iconcologia.net Keywords: carcinoma-associated fibroblasts, microenvironment-mediated drug resistance, colorectal cancer, resistance, chemotherapy Received: May 11, 2016 Accepted: July 19, 2016 Published: August 08, 2016 ABSTRACT The importance of tumor microenvironment (TME) as a relevant contributor to cancer progression and its role in the development of de novo resistance to targeted therapies has become increasingly apparent. However, the mechanisms of microenvironment-mediated drug resistance for nonspecific conventional chemotherapeutic agents, such as platinum compounds or antimetabolites, are still unclear. Here we describe a mechanism induced by soluble factors released by carcinoma-associated fibroblasts (CAFs) that induce the translocation of AKT, Survivin and P38 to the nucleus of tumor cells. These changes are guided to ensure DNA repair and the correct entrance and exit from mitosis in the presence of chemotherapy. We used conditioned media (CM) from normal-colonic fibroblasts and paired CAFs to assess dose response curves of oxaliplatin and 5-fluorouracil, separately or combined, compared with standard culture medium. We also evaluated a colony-forming assay and cell death to demonstrate the protective role of CAF-CM. Immunofluorescence confirmed the translocation of AKT, P38 and Survivin to the nucleus induced by CAF-soluble factors. We also have shown that STAT3 or P38 inhibition provides a promising strategy for overcoming microenvironment-mediated resistance. Conversely, pharmacologic AKT inhibition induces an antagonistic effect that relieves a cMET and STAT3-mediated compensatory feedback that might explain the failure of AKT inhibitors in the clinic so far.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.11121

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 59

Metadata

Authors
Gonçalves-Ribeiro, S., Díaz-Maroto, N. G., Berdiel-Acer, M., Soriano, A., Guardiola, J., Martínez-Villacampa, M., Salazar, R., Capellà, G., Villanueva, A., Martínez-Balibrea, E., & Molleví, D. G.
Venue
Oncotarget
Published
2016-08-08
Volume
7
Issue
37
Pages
59766-59780
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2509579261
Cited by
59
References
8
FWCI
2.32
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.